Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.37 Insider Own4.17% Shs Outstand36.68M Perf Week-11.75%
Market Cap112.97M Forward P/E- EPS next Y-1.53 Insider Trans0.00% Shs Float35.15M Perf Month-5.52%
Income-43.89M PEG- EPS next Q-0.34 Inst Own20.49% Short Float19.48% Perf Quarter-44.40%
Sales0.00M P/S- EPS this Y-0.36% Inst Trans-2.52% Short Ratio7.16 Perf Half Y-50.00%
Book/sh1.01 P/B3.04 EPS next Y-9.68% ROA-63.85% Short Interest6.85M Perf Year-57.37%
Cash/sh1.82 P/C1.70 EPS next 5Y- ROE-112.25% 52W Range2.59 - 10.27 Perf YTD-38.03%
Dividend Est.- P/FCF- EPS past 5Y42.97% ROI-81.36% 52W High-70.01% Beta1.83
Dividend TTM- Quick Ratio4.56 Sales past 5Y0.00% Gross Margin- 52W Low18.92% ATR (14)0.31
Dividend Ex-Date- Current Ratio4.56 EPS Y/Y TTM5.11% Oper. Margin0.00% RSI (14)37.97 Volatility8.84% 9.29%
Employees25 Debt/Eq0.65 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price13.00
Option/ShortYes / Yes LT Debt/Eq0.45 EPS Q/Q4.06% Payout- Rel Volume0.52 Prev Close3.12
Sales Surprise- EPS Surprise18.19% Sales Q/Q- EarningsMay 15 BMO Avg Volume956.13K Price3.08
SMA20-13.39% SMA50-15.57% SMA200-36.20% Trades Volume495,712 Change-1.28%
Date Action Analyst Rating Change Price Target Change
Nov-01-22Initiated B. Riley Securities Buy $10
Jun-28-21Initiated Cantor Fitzgerald Overweight $25
Nov-10-20Upgrade H.C. Wainwright Neutral → Buy $6
May-27-20Initiated Alliance Global Partners Buy $4
Mar-09-20Initiated Noble Capital Markets Outperform $5.45
Oct-24-19Initiated Chardan Capital Markets Buy $10
May-15-24 12:52PM
May-10-24 05:49AM
May-09-24 05:46PM
08:00AM Loading…
May-07-24 08:00AM
May-03-24 08:00AM
May-02-24 08:00AM
Apr-23-24 08:00AM
Mar-28-24 10:24AM
Mar-27-24 11:33PM
08:00AM Loading…
Mar-20-24 08:00AM
Mar-13-24 10:55AM
Jan-22-24 04:45PM
Jan-16-24 08:00AM
Jan-02-24 12:00PM
Dec-04-23 04:50PM
Nov-28-23 07:30AM
Nov-15-23 01:03PM
Nov-14-23 12:19PM
Nov-09-23 08:00AM
Nov-07-23 08:00AM
Oct-23-23 08:00AM
08:00AM Loading…
Oct-11-23 08:00AM
Oct-03-23 07:00AM
Oct-02-23 08:00AM
Sep-26-23 08:00AM
Sep-25-23 08:00AM
Sep-20-23 04:05PM
Sep-13-23 08:00AM
Sep-06-23 04:05PM
Aug-29-23 11:32AM
Aug-16-23 08:00AM
Aug-14-23 11:42PM
Aug-07-23 08:00AM
Aug-02-23 08:00AM
Jul-25-23 08:00AM
Jul-17-23 08:00AM
Jul-11-23 08:00AM
Jun-30-23 04:05PM
Jun-20-23 08:00AM
Jun-14-23 08:00AM
Jun-05-23 02:52PM
May-25-23 05:00PM
May-18-23 08:00AM
May-17-23 01:54PM
May-15-23 09:46PM
May-04-23 08:00AM
Apr-27-23 08:00AM
Apr-24-23 08:00AM
Apr-12-23 08:00AM
Apr-03-23 08:00AM
Mar-30-23 08:28AM
Mar-29-23 07:30AM
Mar-28-23 07:30AM
Mar-16-23 08:00AM
Mar-07-23 08:00AM
Mar-01-23 08:00AM
Feb-27-23 08:00AM
Feb-16-23 08:00AM
Feb-15-23 09:00AM
Feb-08-23 04:00PM
Feb-06-23 08:00AM
Jan-26-23 08:00AM
Jan-13-23 08:00AM
Jan-03-23 11:13AM
Dec-29-22 10:29AM
Dec-28-22 10:39AM
Dec-15-22 08:00AM
Dec-05-22 08:05AM
Nov-21-22 08:00AM
Nov-14-22 07:30AM
Nov-07-22 08:00AM
Oct-31-22 08:00AM
Oct-28-22 01:23PM
Oct-27-22 08:00AM
Oct-25-22 08:00AM
Oct-20-22 09:33AM
Oct-19-22 08:00AM
Oct-17-22 08:00AM
Oct-14-22 11:00AM
Oct-12-22 08:00AM
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its product, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.